Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KRYS with free AI briefings, catalyst countdowns, and dilution alerts.

KRYS · Krystal Biotech, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$911.9M Cash on Hand
CF+ Cash Runway
Follow KRYS by email Get an email when KRYS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KRYS, unsubscribe in one click. Privacy

📣 What KRYS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Topical Beremagene Geperpavec Dystrophic Epidermolysis Bullosa Phase 3 · NCT04491604 Completed
Open Label Topical Beremagene Geperpavec (B-VEC) Dystrophic Epidermolysis Bullosa Phase 3 · NCT04917874 Completed
KB803 Dystrophic Epidermolysis Bullosa Phase 3 · NCT07016750 Recruiting
Cytotoxic Chemotherapeutic Agent Lung Cancer, Non-small Cell Phase 1/2 · NCT06228326 Recruiting
KB801 Neurotrophic Keratitis Phase 1/2 · NCT06999733 Recruiting
Oncolytic HSV-1 Expressing IL-2 and IL-12 KB707 Cancer Phase 1/2 · NCT05970497 Recruiting
KB304 Wrinkles in Decolletage Phase 1/2 · NCT06724900 Active not recruiting
KB105 Autosomal Recessive Ichthyosis Phase 2 · NCT05735158 Unknown
KB408 (Nebulization) Alpha 1-Antitrypsin Deficiency Phase 1 · NCT06049082 Recruiting
KB407 (Nebulization) Cystic Fibrosis Phase 1 · NCT05504837 Recruiting
KB301 Skin Roughness Phase 1 · NCT04540900 Active not recruiting
KB111 Hailey Hailey Disease Early Phase 1 · NCT07717346 Recruiting

Also used in these trials (approved or third-party drugs, not KRYS's own candidates): Pembrolizumab, Nivolumab And Relatlimab-Rmbw, Docetaxel Anhydrous.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KRYS holds $911.9M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KRYS files for a raise →

👥 Who Owns KRYS

Insiders 10.8% Institutions (591 holders) 89.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 3,427,645 11.57% 2026-09-30
Krish S Krishnan
President and CEO, Director, 10% owner · +63,389 options
Insider 1,565,253 5.28% 2026-09-04
Suma Krishnan
President, R&D, Director, 10% owner · +93,892 options
Insider 1,493,155 5.04% 2026-09-04
Daniel Janney
Director · +6,658 options
Insider 73,293 0.25% 2026-02-27
Dino A Rossi
Director · +6,658 options
Insider 46,500 0.16% 2026-11-12
Kathryn Romano
Chief Accounting Officer · +41,517 options
Insider 22,366 0.08% 2026-02-27
Laurent Louis Jean Goux
EVP, Head of International
Insider 919 0.00% 2026-03-01

Share count 29,633,472 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KRYS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KRYS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.